Logo

RNTX

Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc. • NASDAQ
$1.57 ▲ 1.95% (+0.03)
Market Cap $41.27 M
52w High $3.50
52w Low $1.04
Dividend Yield 0%
P/E -0.53
Volume 85.03K
Outstanding Shares 26.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.492M ▼ $-5.581M ▲ 0% $-0.21 ▲ $-5.581M ▲
Q2-2025 $0 $6.871M ▲ $-6.822M ▼ 0% $-0.28 ▲ $-6.87M ▼
Q1-2025 $0 $5.609M ▼ $-5.501M ▲ 0% $-2.51K ▼ $-5.609M ▲
Q4-2024 $0 $5.797M ▼ $-40.981M ▼ 0% $-1.89 ▼ $-42.525M ▼
Q3-2024 $0 $6.071M $-5.847M 0% $-0.27 $-5.847M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.048M ▼ $53.706M ▼ $7.516M ▼ $46.19M ▲
Q2-2025 $5.722M ▼ $57.479M ▼ $54.471M ▲ $3.008M ▼
Q1-2025 $7.428M ▼ $57.628M ▼ $52.754M ▲ $4.874M ▼
Q4-2024 $12.865M ▼ $69.24M ▼ $14.848M ▼ $54.392M ▲
Q3-2024 $17.652M $104.217M $53.99M $50.227M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.581M ▲ $-3.548M ▲ $0 $1.9M ▼ $-1.674M ▲ $-3.548M ▲
Q2-2025 $-6.822M ▼ $-6.418M ▼ $0 $4.712M ▲ $-1.706M ▲ $-6.418M ▼
Q1-2025 $-5.501M ▲ $-6.175M ▼ $0 $738K ▲ $-5.437M ▼ $-6.175M ▼
Q4-2024 $-40.981M ▼ $-4.812M ▼ $0 $1K ▲ $-4.812M ▼ $-4.812M ▼
Q3-2024 $-5.847M $-3.819M $0 $-446K $-4.265M $-3.819M

Five-Year Company Overview

Income Statement

Income Statement Rein Therapeutics is a classic early-stage biotech: it has essentially no product revenue yet and is running at a loss. The small operating and net losses reported reflect research, development, and overhead costs without any offsetting sales. Earnings per share have been negative for several years, which is typical for a company that is still in the clinical trial phase and not yet commercial. The income statement tells a story of a company investing in its pipeline with the expectation that any potential payoff, if it comes, is still several years away and highly uncertain.

Balance Sheet

Balance Sheet The balance sheet is very small and lean, with limited assets and a modest cash position. There is no financial debt, which reduces interest obligations but also means the company mainly relies on equity and external financing agreements to fund operations. Shareholders’ equity has moved around but remains quite low in absolute terms, suggesting a thin financial cushion. Overall, the balance sheet looks fragile: it is clean but not deep, and the company’s ability to withstand setbacks or delays in trials is constrained by its limited resources.

Cash Flow

Cash Flow Cash flows are consistently negative from operations, reflecting ongoing spending on R&D and corporate costs without incoming revenue. Free cash flow is also negative and has been so for multiple years, showing a steady cash burn pattern rather than heavy one-time investments. With essentially no capital spending needs, almost all cash outflow is tied to running the business and advancing the pipeline. This profile is typical for a development-stage biotech, but it also means the company will likely need periodic capital raises or partnerships to keep funding its clinical programs.

Competitive Edge

Competitive Edge Rein is positioned as a niche player focusing on serious lung and fibrotic diseases where treatment options remain limited. Its lead drug candidate, LTI-03, aims to both slow fibrosis and support tissue repair, which is a differentiated angle compared with drugs that mainly try to slow disease progression. Orphan Drug Designation and targeted inhaled delivery add to its potential competitive edge if the drug proves safe and effective. However, the company is very small, has no marketed products, and operates in a field where large pharmaceutical firms already have established therapies and deep resources. Its competitive position therefore depends heavily on clinical trial success and on its ability to form strong partnerships or scale up if its data are compelling.

Innovation and R&D

Innovation and R&D The core of Rein’s value lies in its science. The company is building a fibrosis-focused platform around the caveolin-1 pathway, with LTI-03 as a first-in-class inhaled peptide designed for idiopathic pulmonary fibrosis and other lung conditions. Its approach combines anti-fibrotic and regenerative goals, which, if validated in clinical trials, could represent a meaningful step beyond current standards of care. Additional assets like LTI-01 for pleural effusions and an early cystic fibrosis program broaden the pipeline and show a clear thematic focus on lung and fibrotic disorders. Patent protection, orphan and fast track designations, and a shift away from oncology to this narrower specialty indicate a deliberate R&D strategy, but all key programs remain in clinical or preclinical stages, so scientific and regulatory risk is still high.

Summary

Rein Therapeutics is a very early-stage, pre-revenue biotech that has reoriented itself around orphan pulmonary and fibrotic diseases. Financially, it has modest resources, no debt, ongoing losses, and a steady cash burn, which makes continued access to capital a central issue. Strategically, its potential rests on a differentiated scientific approach and several promising but unproven drug candidates, led by LTI-03. The company’s future hinges on successful execution of mid-stage trials, the quality of forthcoming clinical data, and its ability to secure funding or partners to carry programs through later-stage development. This combination of high scientific potential and high execution and financing risk is typical for small clinical-stage biopharmaceutical firms.

NEWS

October 9, 2025 · 7:30 AM UTC

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Read more

September 17, 2025 · 7:30 AM UTC

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Read more